2024
Risk Score for Hepatocellular Cancer in Adults Without Viral Hepatitis or Cirrhosis
Ilagan-Ying Y, Gordon K, Tate J, Lim J, Torgersen J, Re V, Justice A, Taddei T. Risk Score for Hepatocellular Cancer in Adults Without Viral Hepatitis or Cirrhosis. JAMA Network Open 2024, 7: e2443608. PMID: 39504020, PMCID: PMC11541635, DOI: 10.1001/jamanetworkopen.2024.43608.Peer-Reviewed Original ResearchConceptsClassification of DiseasesBody mass indexRisk scoreNinth Revision and International Statistical Classification of DiseasesMass indexAlcohol useInternational Statistical Classification of DiseasesStatistical Classification of DiseasesElectronic health recordsNon-Hispanic blacksInternational Classification of DiseasesNon-Hispanic whitesClinical Modification diagnosisHepatocellular carcinoma risk scoreRisk of hepatocellular carcinomaCox proportional hazards regression modelsValidation sampleHigh-risk individualsProportional hazards regression modelsHCC risk factorsFIB-4Multivariate risk scoreHepatocellular carcinomaHazards regression modelsViral hepatitisA Validated Algorithm to Identify Hepatic Decompensation in the Veterans Health Administration Electronic Health Record System
Haque L, Tate J, Chew M, Caniglia E, Taddei T, Re V. A Validated Algorithm to Identify Hepatic Decompensation in the Veterans Health Administration Electronic Health Record System. Pharmacoepidemiology And Drug Safety 2024, 33: e70024. PMID: 39477692, DOI: 10.1002/pds.70024.Peer-Reviewed Original ResearchConceptsVeterans Health Administration dataHealth administrative dataAdministrative dataElectronic health record systemsHealth record systemsInternational Classification of DiseasesCoding algorithmOutpatient International Classification of DiseasesPositive predictive valueClassification of DiseasesHepatic decompensationDiagnosis codesPharmacoepidemiologic researchMedical recordsVeteransRecording systemValidation algorithmAlgorithmChronic liver diseaseDecompensationLiver diseasePredictive valueRecordsDiagnosisScreening for Hepatocellular Carcinoma and Survival in Patients With Cirrhosis After Hepatitis C Virus Cure
Mezzacappa C, Kim N, Vutien P, Kaplan D, Ioannou G, Taddei T. Screening for Hepatocellular Carcinoma and Survival in Patients With Cirrhosis After Hepatitis C Virus Cure. JAMA Network Open 2024, 7: e2420963. PMID: 38985470, PMCID: PMC11238019, DOI: 10.1001/jamanetworkopen.2024.20963.Peer-Reviewed Original ResearchConceptsHepatitis C virus cureHepatitis C virusAssociated with improved overall survivalHepatocellular carcinoma diagnosisEarly-stage hepatocellular carcinomaImproved overall survivalOverall survivalHepatocellular carcinomaFollow-upHCC screeningCurative treatmentCumulative incidence of hepatocellular carcinomaDirect-acting antiviral (DAA) therapyCohort studyVeterans Affairs health care systemIncidence of hepatocellular carcinomaRisk of hepatocellular carcinomaCohort study of personsHepatitis C virus cirrhosisDiagnosis of hepatocellular carcinomaLikelihood of curative treatmentYears of follow-upHealth care systemHepatocellular carcinoma screeningHCV-related cirrhosisIdentification of hepatic steatosis among persons with and without HIV using natural language processing
Torgersen J, Skanderson M, Kidwai-Khan F, Carbonari D, Tate J, Park L, Bhattacharya D, Lim J, Taddei T, Justice A, Re V. Identification of hepatic steatosis among persons with and without HIV using natural language processing. Hepatology Communications 2024, 8: e0468. PMID: 38896066, PMCID: PMC11186806, DOI: 10.1097/hc9.0000000000000468.Peer-Reviewed Original ResearchConceptsImaging ReportingSteatotic liver diseaseHIV statusHepatic steatosisPrevalence of metabolic comorbiditiesImaging studiesVeterans Aging Cohort StudyCompare patient characteristicsPositive predictive valueAlcohol use disorderAging Cohort StudyIdentification of hepatic steatosisHIV infectionHepatitis BMetabolic comorbiditiesNatural language processing algorithmsRadiological studiesCohort studyPatient characteristicsClinical reviewLiver diseaseHIVPredictive valueUse disorderClinical image reports
2023
Enhanced Identification of Hispanic Ethnicity Using Clinical Data
Ochoa-Allemant P, Tate J, Williams E, Gordon K, Marconi V, Bensley K, Rentsch C, Wang K, Taddei T, Justice A, Cohorts F. Enhanced Identification of Hispanic Ethnicity Using Clinical Data. Medical Care 2023, 61: 200-205. PMID: 36893404, PMCID: PMC10114212, DOI: 10.1097/mlr.0000000000001824.Peer-Reviewed Original ResearchConceptsBurden of diseaseHispanic patientsCountry of birthClinical dataHispanic ethnicityNon-Hispanic white patientsSex-adjusted prevalenceChronic liver diseaseHuman immunodeficiency virusDemographic characteristicsElectronic health record dataHealth careHealth record dataPrevalence of conditionsUS health care systemMedicare administrative dataHealth care systemWhite patientsLiver diseaseImmunodeficiency virusSelf-reported ethnicityHigh prevalenceGastric cancerHepatocellular carcinomaVeteran population
2022
Oral Cyanobacteria and Hepatocellular Carcinoma
Hernandez BY, Zhu X, Risch HA, Lu L, Ma X, Irwin ML, Lim JK, Taddei TH, Pawlish KS, Stroup AM, Brown R, Wang Z, Wong LL, Yu H. Oral Cyanobacteria and Hepatocellular Carcinoma. Cancer Epidemiology Biomarkers & Prevention 2022, 31: 221-229. PMID: 34697061, PMCID: PMC8755591, DOI: 10.1158/1055-9965.epi-21-0804.Peer-Reviewed Original ResearchConceptsHepatitis B virusHepatitis C virusHepatocellular carcinomaRisk factorsLiver diseaseHCC casesOral microbiomeU.S. case-control studyIndependent risk factorChronic liver diseaseFatty liver diseaseHCC risk factorsGut microbial alterationsType 2 diabetesCase-control studyLiver cancer developmentNSAID useAspirin useC virusB virusHCC riskNegative historyOral samplesSignificant associationCancer development
2021
Coronavirus Disease 2019 Vaccination Is Associated With Reduced Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Death in Liver Transplant Recipients
John BV, Deng Y, Khakoo NS, Taddei TH, Kaplan DE, Dahman B. Coronavirus Disease 2019 Vaccination Is Associated With Reduced Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Death in Liver Transplant Recipients. Gastroenterology 2021, 162: 645-647.e2. PMID: 34758352, PMCID: PMC8572555, DOI: 10.1053/j.gastro.2021.11.001.Peer-Reviewed Original ResearchConceptsAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSyndrome coronavirus 2 infectionCoronavirus disease 2019 (COVID-19) vaccinationCoronavirus 2 infectionLiver transplant recipientsTransplant recipientsVaccinationInfectionRecipientsAssociation of BNT162b2 mRNA and mRNA-1273 Vaccines With COVID-19 Infection and Hospitalization Among Patients With Cirrhosis
John BV, Deng Y, Scheinberg A, Mahmud N, Taddei TH, Kaplan D, Labrada M, Baracco G, Dahman B. Association of BNT162b2 mRNA and mRNA-1273 Vaccines With COVID-19 Infection and Hospitalization Among Patients With Cirrhosis. JAMA Internal Medicine 2021, 181: 1306-1314. PMID: 34254978, PMCID: PMC8278308, DOI: 10.1001/jamainternmed.2021.4325.Peer-Reviewed Original ResearchConceptsCOVID-19 infectionCOVID-19-related hospitalizationBNT162b2 mRNAFirst doseCohort studySecond doseMRNA vaccinesClinical trialsControl groupPropensity-matched control groupPhase 3 clinical trialsCOVID-19 mRNA vaccinesAssociation of vaccinationRetrospective cohort studyUS veteran populationAssociation of receiptVeterans Health AdministrationCoronavirus disease 2019COVID-19 hospitalizationMRNA vaccine administrationCOVID-19Vaccine recipientsImmune dysregulationModerna mRNAMedian ageMale Sex Is Associated With Higher Rates of Liver‐Related Mortality in Primary Biliary Cholangitis and Cirrhosis
John BV, Aitcheson G, Schwartz KB, Khakoo NS, Dahman B, Deng Y, Goldberg D, Martin P, Taddei T, Levy C, Kaplan DE. Male Sex Is Associated With Higher Rates of Liver‐Related Mortality in Primary Biliary Cholangitis and Cirrhosis. Hepatology 2021, 74: 879-891. PMID: 33636012, DOI: 10.1002/hep.31776.Peer-Reviewed Original ResearchConceptsPrimary biliary cholangitisLiver-related deathHepatocellular carcinomaBiliary cholangitisMale sexTime-updated Cox proportional hazards modelsCox proportional hazards modelUrsodeoxycholic acid responseLiver-related mortalityHigher unadjusted ratesRisk of deathVeterans Health AdministrationProportional hazards modelAssociation of sexImpact of sexPBC cirrhosisMale patientsUnadjusted ratesWorse outcomesTotal bilirubinCirrhosisLarge cohortHigh riskHazards modelTransplantationProtease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation
Torgersen J, Newcomb CW, Carbonari DM, Rentsch CT, Park LS, Mezochow A, Mehta RL, Buchwalder L, Tate JP, Bräu N, Bhattacharya D, Lim JK, Taddei TH, Justice AC, Lo Re V. Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation. Journal Of Hepatology 2021, 75: 1312-1322. PMID: 34333102, PMCID: PMC8604762, DOI: 10.1016/j.jhep.2021.07.021.Peer-Reviewed Original ResearchConceptsSevere hepatic dysfunctionBaseline FIB-4Acute liver injuryHepatic dysfunctionInhibitor-based treatmentHepatic decompensationFIB-4Liver injuryHigh riskDAA therapyHazard ratioAdvanced liver fibrosis/cirrhosisRisk of ALIProtease inhibitor-based regimensProtease inhibitor-based treatmentLiver fibrosis/cirrhosisInhibitor-based regimensHepatitis C infectionSevere liver dysfunctionFibrosis/cirrhosisInhibitor-based therapyAminotransferase elevationChronic HCVALT elevationC infectionThe effect of chronic viral hepatitis on prognostic value of inflammatory biomarkers in hepatocellular carcinoma
Sellers CM, Uhlig J, Ludwig JM, Pollak JS, Taddei TH, Stein SM, Lim JK, Kim HS. The effect of chronic viral hepatitis on prognostic value of inflammatory biomarkers in hepatocellular carcinoma. Cancer Medicine 2021, 10: 5395-5404. PMID: 34318618, PMCID: PMC8366096, DOI: 10.1002/cam4.3573.Peer-Reviewed Original ResearchConceptsChronic viral hepatitisViral hepatitisHepatocellular carcinomaMultivariable analysisMedian OSNLR groupHepatitis CKaplan-Meier overall survival curvesCox hazard proportional modelHigher median OSLow baseline NLROverall survival curvesTertiary care institutionBaseline NLRDecreased OSNonviral hepatitisHigh NLRInflammatory biomarkersLow NLRMultivariable adjustmentOverall survivalLymphocyte ratioPrognostic valueRetrospective studyPrognostic relevanceFactors Associated With Access to and Receipt of Liver Transplantation in Veterans With End-stage Liver Disease
Kanwal F, Hernaez R, Liu Y, Taylor TJ, Rana A, Kramer JR, Naik AD, Smith D, Taddei T, Asch SM. Factors Associated With Access to and Receipt of Liver Transplantation in Veterans With End-stage Liver Disease. JAMA Internal Medicine 2021, 181: 949-959. PMID: 34028505, PMCID: PMC8145153, DOI: 10.1001/jamainternmed.2021.2051.Peer-Reviewed Original ResearchConceptsEnd-stage liver diseaseAdvanced liver diseaseLiver diseaseLiver transplantationCohort studyMedical recordsOrgan transplantsVeterans Affairs Health Care SystemLower ratesRetrospective cohort studyWait-listed patientsAfrican American patientsComprehensive electronic medical recordsElectronic medical recordsHealth care systemReferral stepsLiver allograftsLiver transplantAdult patientsAlcohol etiologyLow annual incomePatient ageCurative therapyLiver cirrhosisSodium scoreUrsodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated Cirrhosis
John BV, Khakoo NS, Schwartz KB, Aitchenson G, Levy C, Dahman B, Deng Y, Goldberg DS, Martin P, Kaplan DE, Taddei TH. Ursodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated Cirrhosis. The American Journal Of Gastroenterology 2021, 116: 1913-1923. PMID: 33989225, PMCID: PMC8410631, DOI: 10.14309/ajg.0000000000001280.Peer-Reviewed Original ResearchConceptsLiver-related deathPrimary biliary cholangitisUDCA responseHepatic decompensationHepatocellular carcinomaUrsodeoxycholic acidUDCA respondersPortal hypertensionPartial respondersBiliary cholangitisTime-updated Cox proportional hazards modelsCox proportional hazards modelUrsodeoxycholic acid responseLiver-related mortalityRetrospective cohort studyProportional hazards modelPBC cirrhosisCompensated cirrhosisCohort studyMale patientsClinical benefitUnadjusted ratesCirrhosisReduced mortalityDecompensationRisk Prediction Models for Post‐Operative Mortality in Patients With Cirrhosis
Mahmud N, Fricker Z, Hubbard RA, Ioannou GN, Lewis JD, Taddei TH, Rothstein KD, Serper M, Goldberg DS, Kaplan DE. Risk Prediction Models for Post‐Operative Mortality in Patients With Cirrhosis. Hepatology 2021, 73: 204-218. PMID: 32939786, PMCID: PMC7902392, DOI: 10.1002/hep.31558.Peer-Reviewed Original ResearchConceptsMayo risk scoreVeterans Affairs Surgical Quality Improvement ProgramEnd-stage liver diseaseLiver diseaseSurgical proceduresMELD-NaPostoperative mortalitySurgical Quality Improvement ProgramLiver disease cohortSurgical risk modelsPost-operative mortalityRetrospective cohort studyFatty liver diseasePreoperative risk stratificationMultivariable logistic regressionU.S. medical centersQuality Improvement ProgramRisk prediction modelPopulation-level dataPugh scoreAnesthesiologists classificationChild-TurcottePreoperative albuminCohort studyPostoperative riskMortality and Hepatic Decompensation in Patients With Cirrhosis and Atrial Fibrillation Treated With Anticoagulation
Serper M, Weinberg EM, Cohen JB, Reese PP, Taddei TH, Kaplan DE. Mortality and Hepatic Decompensation in Patients With Cirrhosis and Atrial Fibrillation Treated With Anticoagulation. Hepatology 2021, 73: 219-232. PMID: 32267547, PMCID: PMC7541418, DOI: 10.1002/hep.31264.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsEffect of anticoagulationAtrial fibrillationCause mortalityMarginal structural modelsHepatic decompensationIschemic strokeMajor adverse cardiovascular eventsAdvanced liver diseaseAdverse cardiovascular eventsIncident atrial fibrillationSplanchnic vein thrombosisPropensity-score matchingCardiovascular eventsOral anticoagulantsVein thrombosisFinal cohortLiver diseaseTime-dependent confoundingAnticoagulationLower incidenceMedical CenterCirrhosisWarfarinU.S. veterans
2020
SGLT2 inhibitors in patients with cirrhosis and diabetes mellitus: A tertiary center cohort study and insights about a potential therapeutic target for portal hypertension
Saffo S, Garcia‐Tsao G, Taddei T. SGLT2 inhibitors in patients with cirrhosis and diabetes mellitus: A tertiary center cohort study and insights about a potential therapeutic target for portal hypertension. Journal Of Diabetes 2020, 13: 265-269. PMID: 33210815, DOI: 10.1111/1753-0407.13136.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBenzhydryl CompoundsCohort StudiesDiabetes Mellitus, Type 2FemaleGlucosidesGlycated HemoglobinHumansHypertension, PortalLiver CirrhosisMaleMiddle AgedOutcome Assessment, Health CarePolyuriaSodium-Glucose Transporter 2 InhibitorsTertiary Care CentersUrinary Tract InfectionsYoung AdultConceptsSGLT2 inhibitorsPortal hypertensionDiabetes mellitusSodium-glucose cotransporter 2 inhibitorsGlucose cotransporter 2 inhibitorsCenter cohort studyCotransporter 2 inhibitorsCohort of patientsPotential therapeutic targetFavorable pleiotropic effectsCohort studyRenal diseaseClinical trialsClinical dataTherapeutic targetPatientsCirrhosisHypertensionMellitusOngoing evaluationInhibitorsPleiotropic effectsCohortDiseaseTrialsImpact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study
Hajiev S, Allara E, Motedayеn Aval L, Arizumi T, Bettinger D, Pirisi M, Rimassa L, Pressiani T, Personeni N, Giordano L, Kudo M, Thimme R, Park JW, Taddei TH, Kaplan DE, Ramaswami R, Pinato DJ, Sharma R. Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study. British Journal Of Cancer 2020, 124: 407-413. PMID: 33071284, PMCID: PMC7852559, DOI: 10.1038/s41416-020-01116-9.Peer-Reviewed Original ResearchConceptsOverall survivalHepatocellular carcinomaCohort studySorafenib-related toxicityInternational cohort studyMedian overall survivalMulticentre cohort studyLow-dose therapyCommon prognostic factorsSimilar overall incidenceDoses of sorafenibImpact of ageConclusionsClinical outcomesSorafenib 800Sorafenib dosingElderly patientsOlder patientsPrognostic factorsOverall incidenceClinical efficacyLiver functionLarge tumorsMultivariable modelGrade 2PatientsPatterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: A nationwide cohort study
Rentsch CT, Kidwai-Khan F, Tate JP, Park LS, King JT, Skanderson M, Hauser RG, Schultze A, Jarvis CI, Holodniy M, Re V, Akgün KM, Crothers K, Taddei TH, Freiberg MS, Justice AC. Patterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: A nationwide cohort study. PLOS Medicine 2020, 17: e1003379. PMID: 32960880, PMCID: PMC7508372, DOI: 10.1371/journal.pmed.1003379.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBetacoronavirusBlack or African AmericanClinical Laboratory TechniquesCohort StudiesCoronavirus InfectionsCOVID-19COVID-19 TestingEthnicityFemaleHispanic or LatinoHumansMaleMiddle AgedPandemicsPneumonia, ViralRetrospective StudiesSARS-CoV-2United StatesVeteransWhite PeopleYoung AdultConceptsCOVID-19 testingRace/ethnicityCohort studyWhite individualsSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionAcute respiratory syndrome coronavirus 2 infectionSyndrome coronavirus 2 infectionSARS-CoV-2 infectionCOVID-19Large integrated healthcare systemCoronavirus 2 infectionNationwide cohort studyRetrospective cohort studyCoronavirus disease 2019Site of careIntegrated healthcare systemNon-Hispanic blacksPositive test resultsNon-Hispanic whitesClinical characteristicsMultivariable adjustmentComorbid conditionsMedication historyEthnic minority communitiesDisease 2019Liver Pathologic Changes After Direct-Acting Antiviral Agent Therapy and Sustained Virologic Response in the Setting of Chronic Hepatitis C Virus Infection.
Celli R, Saffo S, Kamili S, Wiese N, Hayden T, Taddei T, Jain D. Liver Pathologic Changes After Direct-Acting Antiviral Agent Therapy and Sustained Virologic Response in the Setting of Chronic Hepatitis C Virus Infection. Archives Of Pathology & Laboratory Medicine 2020, 145: 419-427. PMID: 32810870, PMCID: PMC10960369, DOI: 10.5858/arpa.2020-0008-oa.Peer-Reviewed Original ResearchConceptsHepatocellular carcinomaHCC developmentChronic hepatitis C virus (HCV) infectionChronic viral hepatitis C infectionHepatitis C virus infectionViral hepatitis C infectionTissue polymerase chain reactionAntiviral agent therapyLiver histologic findingsLiver pathologic changesNon-SVR groupOccult HCV infectionPersistent liver inflammationSuccessful DAA therapyC virus infectionHepatitis C infectionSubset of patientsDegree of inflammationNumber of patientsPresence of virusDAA therapySVR patientsVirologic responseC infectionHCV infectionGrade 1 Acute on Chronic Liver Failure Is a Predictor for Subsequent Grade 3 Failure
Mahmud N, Sundaram V, Kaplan DE, Taddei TH, Goldberg DS. Grade 1 Acute on Chronic Liver Failure Is a Predictor for Subsequent Grade 3 Failure. Hepatology 2020, 72: 230-239. PMID: 31677284, PMCID: PMC7195222, DOI: 10.1002/hep.31012.Peer-Reviewed Original ResearchConceptsChronic liver failureAcute decompensationLiver failureOrgan failureVeterans Health Administration databaseHigh short-term mortalityGrade 1 ACLFGrade 3 ACLFRetrospective cohort studyShort-term mortalityHealth Administration databaseACLF severityTransplant evaluationGastrointestinal bleedCohort studyCirculatory failureHepatic encephalopathyCox regressionACLFStratified analysisHigh riskLower riskPatientsPropensity scoreEuropean Association